Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment

Wanwan Cheng† | Bin Xu† | Haitao Zhang | Shencun Fang‡

Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, 215 Guangzhou Road, Nanjing, Jiangsu, 210029, China

Correspondence Shencun Fang, Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China. Email: fang1984@aliyun.com

Funding information "Six one projects" in Jiangsu Province, Grant/Award Number: LGY2019006

Abstract
Background: Kelch-like ECH-associated protein 1 (KEAP1) has been identified as a cancer driver gene in lung adenocarcinoma (LUAD), and increased evidence has given us clues about the association of KEAP1 mutation and immune characteristics. We assessed the association between KEAP1 mutation and tumor microenvironment in LUAD systematically.

Methods: With the data collected from The Cancer Genome Atlas (TCGA), we evaluated the association of KEAP1 mutation with tumor infiltrating leukocytes (TILs), including dendritic cell, CD8 T cell, CD4 T cell, neutrophil, B cells, and macrophage. Expression differences of the markers of those immune cells were also measured. We further compared the expression of antigen presentation genes and chemokines and the enrichment score of immune-related pathways.

Results: KEAP1 mutation had significant association with lower TILs and cytotoxic T lymphocyte. Strikingly, almost all of antigen presentation genes and chemokine showed lower expression in KEAP1-mutated tumors. Moreover, most of immune-related pathways were less active in KEAP1-mutated tumors. As expected, KEAP1-wild type LUADs favored better overall survival after immunotherapy. Finally, one patient harboring KEAP1 mutation along with a lack of immune cells infiltration in tumor microenvironment failed to respond to checkpoint inhibitor despite high tumor mutational burden (TMB).

Conclusions: KEAP1 mutation has a significant effect on the tumor immune milieu of LUAD and may play as a predictive biomarker of immunotherapy for LUAD patients.

KEYWORDS
immunotherapy, Kelch-like ECH-associated protein 1, lung adenocarcinomas, tumor microenvironment

INTRODUCTION

Lung cancer is a leading cause of cancer-related mortality in the world, with ~2 093 000 newly diagnosed cases in 2018.1 Non-small cell lung cancer (NSCLC) accounts for 80%–85% of lung cancer with a poor 5-year survival rate of ~18%.2 Among NSCLC, the incidence rate of one of its major histological subtypes, lung adenocarcinomas (LUAD), is ~50%. Recent advances in next generation sequencing (NGS) have revealed many vulnerable gene alternations in LUAD including the targetable ones such as the epidermal growth factor receptor (EGFR) gene and translocations of the anaplastic lymphoma kinase (ALK) gene.3 Apart from them, the alternation of Kelch-like ECH-associated protein 1 (KEAP1) gene, encoding the KEAP1, has been found to be associated with LUAD with a frequency of 23% and therefore is considered a cancer driver gene.4 Under normal conditions, it is identified as a substrate adaptor for a Cul3-containing E3 ubiquitin ligase and its main function is to complex with nuclear factor erythroid-2-related factor 2(Nrf2) through a direct protein–protein interaction, maintaining the latter at a low level.5 Because Nrf2 is responsible for organizing a wide range of cellular defense processes, the Nrf2–Keap1 pathway has been considered a major cellular defense pathway.
In recent years, new treatment modalities in NSCLC, such as immunotherapy or its combinations with others like chemotherapy, have strikingly induced durable responses. Specifically, treatments based on immune checkpoint blockade have demonstrated high efficacy in form of a variety of inhibitors such as ipilimumab (anti-CTLA4), nivolumab (anti-PD1), pembrolizumab (anti-PD1), atezolizumab (anti-PD-L1), and avelumab (anti-PD-L1). Likely because of the heterogeneities of inter- and intra-tumors as well as varied tumor micro-environment (TME), only a specific subset of patients can benefit from such treatments, unfortunately. As a result, intensive research has been done to identify potential biomarkers for selecting the patients who are expected to respond well to such treatment modalities. Several studies have shown that PD-L1 expression assessed by immunohistochemistry (IHC), tumor mutational burden (TMB) by NGS, microsatellite instability (MSI) by PCR or NGS, as well as deficient mismatch repair (dMMR) by IHC were associated with response to cancer immune checkpoint blockade treatment. Specifically, PD-L1 expression and TMB are being intensively investigated in NSCLCs. In addition to these two biomarkers, enthusiasm in elucidating the components in TME, such as tumor-infiltrating lymphocytes (TILs) and specific immune genes and pathways, has been reinvigorated, and potential biomarkers are being explored for the identification of patients that benefit from immune checkpoint inhibitors (ICIs) and therapies targeting angiogenesis. Although, as a commonly altered gene like TP53, KRAS, and EGFR in LUAD, changes within tumor immune milieu, and accordingly the clinical implication relevant to the mutation of KEAP1, remains largely unknown. Specifically, the studies are limited to investigating the association between mutations of some specific genes like KEAP1 with TME and the clinical benefit and potential drug targets.

To understand the effect of KEAP1 mutation on the immunity of LUAD, we have associated TIL score with KEAP1 alternation; furthermore, relevant immune marker, human leukocyte antigen (HLA), immune-related pathway and cytokine networks. Finally, Cox models have been applied to assess associations between KEAP1 mutation and disease prognosis and the prediction of patient survival after immunotherapy in LUADs.

**FIGURE 1** Tumor infiltrating leukocytes and KEAP1 mutation status. (a) Infiltration levels of six types of immune cells in LUADs. (b) Six types of immune cells and their infiltration levels in KEAP1-mutated LUADs versus in KEAP1-wild type LUADs. (c) Markers of the immune cells and their expressions in KEAP1-mutated versus wild type LUADs. (d) Association of cytotoxic T lymphocytes (CTL) with KEAP1 mutation in LUADs. Wilcoxon rank-sum test was used to compare difference, and p-value was adjusted with Benjamini–Hochberg method.
**RESULTS**

**KEAP1 mutation is associated with lower infiltration of immune cells in LUAD**

To evaluate the potential association between KEAP1 mutation status and immune microenvironment of the tumor in patients with LUAD, the abundance of infiltrating immune cells was estimated. We collected the abundance of six types of cells including B cells, CD4 T cells, CD8 T cells, dendritic, macrophages, and neutrophils, which were quantitatively calculated by gene expression profiles through RNA-seq from TIMER database. First, dendritic cells had the significantly highest infiltration level, followed by CD8 T cells, CD4 T cells, neutrophils, and B cells, whereas macrophage had the lowest infiltration level (Kruskal-test, p-value <2.2e-16) (Figure 1(a)). Second, the association between KEAP1 mutation status and the infiltration level of each cell type was studied. Among 543 LUAD patients, 96 patients were found to harbor KEAP1 mutation (frequency = 17.6%). Strikingly, the result showed that all of the six immune cell types had significantly lower infiltration levels in KEAP1-mutated LUADs versus KEAP1-wild type (Figure 1(b)), suggesting an overall low immune cell infiltration and low activity of immune environment within KEAP1-mutated LUAD patients. In detail, significant differences of the infiltration between the KEAP1-mutated and wild type LUADs were observed for dendritic cells (adjusted p-value = 3.7e−9), CD8 T cells (adjusted p-value = 0.026), CD4 T cells (adjusted p-value = 1.4e−9), neutrophils (adjusted p-value = 1.9e−6), B cells (adjusted p-value = 3.1e−6), and macrophages (adjusted p-value = 0.00028). Furthermore, we evaluated the abundance for 19 specific immune markers within the six immune cell types (Table S1) and found 17 markers significantly exhibited lower expression levels in KEAP1-mutated LUADs than in KEAP1-wild type LUADs (with adjusted p-value <0.05) (Figure 1(c)), which was consistent with the result above. Only the marker of CD55 on neutrophil was found to have higher (but insignificantly) expression in KEAP1 mutated LUADs with fold change (FC) >1.0 and adjusted p-value = 0.55. All of the results above confirmed that KEAP1-mutated type LUADs are associated with the lower immune cell infiltration abundance. It is, therefore, assumable that KEAP1 mutated LUADs could possibly have lower tumor immunity, compared to the wild type patients. In addition, we estimated the cytotoxic T lymphocyte (CTL) level with the mean expression of its typical markers including CD8A,
As shown in Figure 1(d), KEAP1-mutated LUADs exhibited significantly lower CTL level than KEAP1-wild type LUADs. This further suggested that KEAP1-mutated LUAD patients may harbor the impaired tumor immunity.

KEAP1 mutation is associated with lower human leukocyte antigen (HLA) expression in LUAD

In addition to immune infiltration cell, we were also interested in the expression of HLA molecules, in association

CD8B, GZMA, GZMB, and PRF1 by following Jiang et al. As shown in Figure 1(d), KEAP1-mutated LUADs exhibited significantly lower CTL level than KEAP1-wild type LUADs (p-value = 0.033). This further suggested that KEAP1-mutated LUAD patients may harbor the impaired tumor immunity.

**FIGURE 2** Association of KEAP1 mutation and HLA expression. (a) Boxplot shows expression of the type 1 HLA molecules in KEAP1-wild type and KEAP1-mutated LUADs. (b) Boxplot shows the expression of the type 2 HLA molecules in KEAP1-wild type and KEAP1-mutated LUADs. (c) Boxplot shows the expression of three important HLA related genes in KEAP1-wild type and KEAP1-mutated LUADs. The numeric above the boxplot indicates adjusted p-value. Wilcoxon rank-sum test was used to compare difference, and p-value was adjusted with Benjamini–Hochberg method.
with the mutation of KEAP1. As reported in IPD and IMGT/HLA database, 19 HLA class I and 13 HLA class II molecules have been identified in human genome. In 488 TCGA LUADs, we found that 9 molecules of class I and 13 ones of class II had expression values available. Among them, 7 HLA class I genes were found to have significantly lower expression level in KEAP1-mutated LUADs than in KEAP1-wild type LUADs (Figure 2(a)), and consistently, all of 13 HLA class II genes were found to have significantly lower expression level in KEAP1-mutated LUADs (Figure 2(b)). We searched the literature and were interested in the expression of the HLA-related genes like B2M, NLRC5, and CIITA, in association with KEAP1 mutation. As a result, B2M, as a component of HLA class I, exhibited significantly lower expression in KEAP1-mutated LUADs ($p = 0.001$) (Figure 2(c)), and NLRC5 and CIITA, which play a major role in the transcription of HLA class I and II genes, showed the same trend, with the $p$-values of 0.0014 and 8.5e$-9$, respectively (Figure 2(c)). Taken together, these findings indicated that KEAP1 mutation is likely associated with impaired presenting processes of tumor specific neoepitopes, therefore impairing tumor immunity.

KEAP1 mutation is associated with lower activities of immune-related pathway in LUAD

To further understand the effect of KEAP1 mutation on immune milieu, we performed enrichment analysis on 19 immune-related pathways collected from the KEGG database, and the enrichment score for each pathway and each sample of 488 LUADs was calculated with the algorithm
implemented in the Gene Set Variation Analysis (GSVA), a R software package\textsuperscript{15} to represent the activity of immune-related pathway. As shown in Figure 3, all immune-related pathways had lower enrichment scores in KEAP1-mutated LUADs than in KEAP1-wild type LUADs and 18 of them exhibited significantly lower enrichment scores with adjusted $p$-value $< 0.05$. Among them, both B cell receptor and T cell receptor signaling pathways were markedly downregulated with the significance of $p$-values of $6.7 \times 10^{-9}$ and $6.6 \times 10^{-7}$, respectively. Meanwhile, the pathway involving natural killer cell mediated cytotoxicity was also significantly downregulated in KEAP1-mutated LUADs ($p$-value $= 1.7 \times 10^{-7}$). Consistent with the HLA results above, antigen processing and presentation pathway was also affected ($p$-value $= 2.2 \times 10^{-6}$). Taken together, all of these results confirmed at the level of pathway that KEAP1 mutation could possibly have defective impact on tumor immunity.

**KEAP1 mutation is associated with chemokine network activity in LUAD**

As we know, the migration and positioning of immune cells can be regulated by chemokines. Complex chemokine networks have been found in many cancers and they play important roles in the extent and phenotype of tumor lymphocyte infiltrate, as well as tumor cell growth, survival, migration, and angiogenesis\textsuperscript{20,21}. Up to now, ~40 chemokines and 20 signaling chemokine receptors have been identified in human.\textsuperscript{21} Therefore, the correlation between KEAP1 mutated status and the expression levels of those genes was studies. Through the LUAD data set from TCGA, we found that 18 chemokines and 16 chemokine receptors had notably lower expression levels in KEAP1-mutated samples (Figure 4(a),(b)). Interestingly, those genes are involved in regulating multiple immune-related biological processes such as lymphocyte
migration, neutrophil trafficking, T cell-DC interactions, T helper cell response, etc.\textsuperscript{21}

Moreover, we evaluated the interaction between chemokine and matched receptor. The results showed that many chemokines and chemokine receptor pairs had lower or even negative correlation coefficients (Figure 4(c)) in KEAP1-mutated group compared to KEAP1-wild type. Among those affected chemokine-receptor pairs, some pairs such as CCL19, CCL21, and CCR7 were involved in T cell and dendritic homing to lymph node;\textsuperscript{22} whereas some pairs play a role in Th2 cells response\textsuperscript{23,24} (e.g., CCL8 and CCR1, CCL13 and CCR2, CCL17 and CCR4), and some pairs contribute to\textsuperscript{25} T cell–dendritic interactions\textsuperscript{26} (e.g., CCL3 and CCR1 and CCL5 and CCR1). Given that chemokine network activity plays an important role in regulating the tumor immunity, it is assumable that the potential way of KEAP1 mutation impacting the immunity as suggested from the results above, might be likely related to damaging the chemokine network activity in LUADs.

**KEAP1 mutation predicts patient survival on immunotherapy**

Finally, we investigated whether KEAP1 mutation can affect the survival of LUAD patients. In detail, neither overall survival (OS) nor relapse-free survival (RFS) were found to have a significant correlation with KEAP1 status in LUADs (OS HR = 1.14, 95% CI = 0.8–1.64, log-rank \( p \)-value = 0.47; RFS HR = 1.09, 95% CI = 0.72–1.66, log-rank \( p \) = 0.68) (Figure 5(a),(b)). However, our further studies suggest that KEAP1 mutation could be a predictive biomarker in immunotherapy with another dataset reported by Samstein et al.\textsuperscript{11} After immunotherapy (PD-1 or PD-L1 inhibitor), KEAP1-wild type
LUADs favored better survival than KEAP1-mutated (OS HR = 1.45, 95% CI = 1.02–2.07, log-rank p-value = 0.038), with median survival 13 and 6 months, respectively. Multivariate Cox regression analysis was performed with various factors, including age, gender, TMB, immune drug-type, and KEAP1 mutated status. KEAP1 was revealed to be an independent predictive biomarker for OS of LUAD patients (HR = 1.62, 95% CI = 1.12–2.33, p-value = 0.01). This result suggests that KEAP1 mutated status could be identified as a predictive rather than a prognostic biomarker for survival on immunotherapy of LUAD patients.

**No response to immunotherapy for a LUAD patient harboring KEAP1 mutation despite high TMB**

A patient diagnosed with lung adenocarcinoma, whose chest computed tomography (CT) revealed a 3 cm × 4 cm mass in the right upper lobe with diffuse metastatic nodules in both lungs. The patient harboring TP53 p.R248W mutation had a favorable immune cell infiltration in tumor microenvironment. The chemotherapy regimen of “pemetrexed plus cisplatin” was administered as a first-line treatment and had a response of partial response characterized by more than 8 months of control. A broad NGS test after recurrence was performed, showing KEAP1 p.R470C and TP53 p.R248W mutations along with a high TMB (28mut/MB). However, multiple immunocytochemistry revealed a low immune cell infiltration and low activity of immune environment. Unfortunately, the patient showed no response to a checkpoint inhibitor (nivolumab) as a second-line treatment (Figure 6).

**DISCUSSION**

In this study, we have performed a comprehensive investigation of KEAP1 gene mutation in LUAD patients with focus on its associations with immune microenvironment of tumor. Importantly, we have shown that LUADs with mutant type of KEAP1 gene carry a suppressed immune milieu from the following findings. First, the assessment of infiltration of immune cells has shown that the major immune cells including B cells, CD4 T cells, CD8 T cells, dendritic cells, macrophages, and neutrophils are downregulated within KEAP1 mutated LUADs and such correlation exhibits a highly statistical significance. Second, the key markers of immune cells are mostly downexpressed in KEAP1-mutated LUADs, consistent with the first
finding. Third, both class I and II of HLA molecules show significantly lower expression levels in KEAP1-mutated LUADs. In addition, we have also comprehensively investigated the general immune-related pathways and specific network of chemokine in this study. Overall, KEAP-mutated LUADs compared to wild type ones have shown lower activities, and 17 pathways exhibit significantly lower pathway enrichment scores even after p-value adjustment. Moreover, chemokine network, which is believed to regulate the migration and positioning of immune cells, has also been specifically studied in association with KEAP1 mutation in LUADs. Not only the multiple immune-related biological processes, but also the interaction between chemokines and their receptors, have shown KEAP1 mutation could impair the immune pathways including the chemokine network, therefore explaining that LUADs with the wild type of this gene could potentially benefit from the immunotherapy. Last, these findings are in line with the previous study of Best et al., which the tumor immunosuppression environment was found to be associated with the loss of KEAP1 and PTEN in LUADs. Taken together, the results above highlight the possibility that KEAP1-wild type tumors are associated with higher tumor immunity and, therefore, may be sensitive to immunotherapy, providing a new treatment modality and biomarker for those LUADs with KEAP1-wild type.

Accordingly, we have evaluated the effects of KEAP1 mutation on disease prognosis from TCGA data and on immunotherapy using PD-1/PD-L1 blockers from previous published data, and the results have shown that there is no significant prognostic effect of KEAP1 mutation. On the contrary, it is therapeutically important to note that there is a predictive power of KEAP1 mutation on the immunotherapy: KEAP1-wild type LUADs favored better survival after immunotherapy than KEAP1-mutated LUADs. The latter result has verified that significant differences of immunogenic were found between mutated KEAP1 and wild type groups in terms of core immune signatures. Therefore, we could conclude that the immune environment is significantly changed within the KEAP1-mutated LUADs and this change has clinical implications, especially for the immunotherapy using PD-L1 blockers.

Our study has limitations. We only have data available for KEAP1 status, survival data after immunotherapy, and a separate set of data for KEAP1 status and RNA-seq data for defining immune milieu. Unfortunately, we do not have samples for assessing all of the three entities simultaneously. Therefore, all the conclusions above have been made based on correlation approach. LUAD patients with all the three measurements available in a future study will further validate the findings in this study. This study demonstrates the potential effect of KEAP1 mutation on tumor immune milieu of LUAD subtype of NSCLC patients, highlighting the potential efficacies of the immunotherapy treatment using PD-L1 blockers in KEAP1-wild type LUADs.

ACKNOWLEDGMENTS

This study was supported by the “Six one projects” in Government of Jiangsu Province (LGY2019006).

CONFLICT OF INTEREST

None of the authors reported a conflict of interest related to the study.

ORCID

Shencun Fang https://orcid.org/0000-0002-4223-5428

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
3. Cardarelli S, Johnson BE. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013;188:770–5.
4. Best SA, Sutherland KD. “Keap”ing a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle. 2018;17:1696–707.
5. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179–91.
6. Corrales L, Scilla K, Caglicev C, Miller K, Oliveira J, Rolfo C. Immunotherapy in lung cancer: a new age in cancer treatment. Adv Exp Med Biol. 2018;995:65–95.
7. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.
8. van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11.
9. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
10. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;515:543–50.
11. Samstein RM, Lee CH, Shousharti AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–6.
12. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
13. Luo W, Friedman MS, Shedd K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics. 2009;10:161.
14. Babrie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–12.
15. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
16. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110.
17. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumour immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.
18. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–8.
19. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2015;43(Database issue):D423–31.
20. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:450–50.
21. Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379.
22. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 1999;189:447–50.
23. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today. 1998;19:568–74.
24. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702.

25. Castriconi R, Carrega P, Dondero A, Bellora F, Casu B, Regis S, et al. Molecular mechanisms directing migration and retention of natural killer cells in human tissues. Front Immunol. 2018;9:2324.

26. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol. 2008;8:675–84.

27. Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D’Ambrosio L, et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020;31:1746–54.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Cheng W, Xu B, Zhang H, Fang S. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment. Thorac Cancer. 2021;12:2458–67. [https://doi.org/10.1111/1759-7714.14089](https://doi.org/10.1111/1759-7714.14089)